

07 November 2025

BSE Limited
Corporate Relationship Department
First Floor, New Trading Ring
Rotunda Building
P.J. Towers, Dalal Street
Mumbai – 400 001.

Dear Sirs,

Sub: Newspaper Advertisement – Unaudited Financial Results for the Quarter/Half-year ended 30th September 2025 pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose here with copies of Extracts of the Unaudited Financial Results of the Company for Quarter/Half-year ended 30th September 2025 published in Mathrubhumi (Malayalam) and Business Line (English) daily newspapers on 07th November, 2025.

You may kindly take the above information on record.

Thanking You,

Yours faithfully,

For KSE Limited

Srividya Damodaran
Company Secretary

Dr Reddy’s to step up focus on emerging markets, India

STRATEGY SHIFT. With a hefty revenue of \$3.8 billion in FY25, the pharma giant plans to foray into Central and South American markets

bl.interview

G Naga Sridhar
Hyderabad

The Indian pharmaceutical industry is undergoing some challenges in the form of pricing pressure in the US market and the issue of tariffs which are yet to impact domestic drug-makers. At the same time, the growth of business in Europe, emerging markets and India has been impressive for many. Major industry players are stepping up focus on these markets even though the US still continues to be the major market. Dr Reddy's Laboratories, with a total revenue of \$3.8 billion

(FY25), has been growing in India and emerging markets. MV Ramana, CEO-Branded Markets (India and Emerging Markets), Dr Reddy's, spoke on the market trends and the company's strategies. *Edited excerpts:*

What is the scenario in the emerging markets and what is your business strategy for the industry and your company?
We're now present across Asia, Russia, CIS, Africa, and Latin America. Our international business spans two key segments: a traditional footprint in Russia and CIS, covering prescription (Rx), OTC, and hospital channels; and institutional operations in 45 emerging markets.

In the domestic market, we have been growing at double digits. We will continue to focus on certain therapeutic areas where we have the endowment

MV RAMANA
CEO-Branded Markets (India and Emerging Markets), Dr Reddy's



This structure enables us to leverage products developed for the US and Europe across these markets, driving double-digit growth. Most emerging markets are brand-driven, and we

continue to build strong brands in both Rx and OTC segments. We've sharpened our capabilities with successful brands like Omez and Nise, and also represent partner brands such as P&G's in select markets. Ad-

ditionally, we're extending innovations licensed for India into emerging markets, where similar healthcare needs exist.

How about the domestic market? What is the product line-up?
In the domestic market, we've been growing at double-digit rates and remain focused on key therapeutic areas where we have strong capabilities. Our strategy is to introduce differentiated and first-to-market products. We've built on our legacy brands like Omez and Razo with the launch of Vonoprazan, and more recently, Tegoprazan — a first in India. BixiBat and Linacotide were also first-time launches, with several more expected.

Our joint venture with Nestlé is progressing well. We're exploring ways to expand consumer health into ethical businesses — especially those that are OTC by definition but currently promoted as prescription, or have the potential to transition to OTC. India's growth story for us is about building strong brands through branded generics, innovative assets, and consumer health. **Down the line, how will be business from India and EMs vis-a-vis US and Europe for the company?**
As Dr Reddy's had completed the acquisition of Haleon Plc's global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category

outside of the US, Europe has become even more meaningful for us. So is the US. The products we expect to launch including complex generics and biosimilars, both US and Europe are important markets in terms of the size and opportunity to grow. India and EMs in the overall sense will continue to be even more important going forward and their contribution is expected to grow. **What is the potential and opportunity for biosimilars in India and emerging markets?**
Most of the biosimilars in India and EMs fall into the segment where there are opportunities to brand the product and to promote it. In many of the emerging markets,

there's also a need to localise the product. So we actually locally manufacture the product in a few countries that benefit local manufacturers. This becomes a platform not only for our own biosimilars but also for our partner products. Hence, there is growth coming in from both Dr Reddy's portfolio as well as the portfolio from the partner products. **What are the new geographies/markets being looked at?**
We already have a presence in the big markets of Russia, Brazil and China. But also in the last couple of years, we've also looked into leveraging our institutional portfolio into Central and South America.

Piramal Pharma's Q2 numbers hit by CDMO destocking

Our Bureau
Mumbai

Piramal Pharma posted a loss of ₹99 crore for the second quarter ended September 30, 2025, impacted by inventory destocking on a commercial, on-patent product in the contract development and manufacturing organisation (CDMO) segment. The drug-maker's revenue from operations for the quarter under review was down 9 per cent at ₹2,044 crore. Nandini Piramal, Chairperson, Piramal Pharma, said, "Year-on-Year (y-o-y) growth in the CDMO business was primarily impacted by inventory destocking in one large on-patent commercial product. Inconsistent recovery in US biopharma funding, along with uncertainties on global trade policies, led to adverse impact on order inflows and customer decision making during H1FY26. However, in September and October 2025, we have seen a significant pick-up in biopharma funding which, if [it] sustains, should lend impetus to increased RFPs and orders going forward." The company's CDMO business for the quarter under review stood at ₹1,044 crore, down 21 per cent. Its Complex Hospital Generics segment was flat at ₹644 crore and the consumer healthcare segment grew by 15 per cent at ₹319 crore. On the consumer healthcare outlook, Piramal told *businessline* that the company's power brands grew close to 20 per cent.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025 (₹ in Crores)								
PARTICULARS	Standalone				Consolidated			
	For the Three Months Ended		For the Half Year Ended		For the Three Months Ended		For the Half Year Ended	
	30-Sep-2025	30-Sep-2024	30-Sep-2025	30-Sep-2024	30-Sep-2025	30-Sep-2024	30-Sep-2025	30-Sep-2024
1. Total Income	759.21	669.54	1,443.62	1,282.19	1,010.23	674.95	1,907.82	1,297.06
2. Net Profit / (Loss) before tax, Exceptional and Extraordinary Items	61.37	56.82	114.59	106.34	84.55	60.00	150.70	119.32
3. Exceptional Items	—	—	—	—	—	—	—	—
4. Net Profit / (Loss) before tax (after Exceptional and Extraordinary items)	61.37	56.82	114.59	106.34	84.55	60.00	150.70	119.32
5. Net Profit / (Loss) after tax	45.51	42.46	84.68	78.86	63.99	45.07	113.88	90.63
6. Total Comprehensive Income	44.95	42.10	83.65	77.97	66.47	48.93	117.16	92.67
7. Cash Profit	68.93	62.22	130.26	117.88	96.50	69.61	175.84	133.67
8. Paid-up-Equity Share Capital (Face Value of ₹ 1/- each)	12.19	12.19	12.19	12.19	12.19	12.19	12.19	12.19
9. Earnings per Equity Share for Profit / (Loss) (Face Value of ₹ 1/-) in Rupees — Basic / Diluted (not annualised for quarters)	3.74	3.48	6.95	6.47	5.25	3.70	9.34	7.44

Note:

- The above is an extract of the detailed format of Quarterly / Half Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Stock Exchange websites www.bseindia.com, www.nseindia.com and Company's website www.pricol.com.
- The Board at its meeting held today, declared an interim dividend of ₹ 2/- per share (200%) for the financial year 2025-26. The same will be paid to the members / beneficial owners, whose name appear in the register of members / register of beneficial owners maintained by the Depositories as on the record date i.e., 14th November, 2025.

6th November 2025
Coimbatore

By Order of the Board
VANITHA MOHAN
CHAIRMAN
DIN : 00002168



Children's Day

Special Issue dated 14th November 2025

Six winners of a PAN-India contest become Guest Editors for this special issue...
Where young voices lead the way!

For the Children By the Children

Collectors' Edition @ ₹ 20 only

SCAN TO SUBSCRIBE

FOLLOW US ON @thehinduworld

PRE-BOOK YOUR COPY WITH YOUR NEWSPAPER AGENT TODAY

For Print Subscription, visit www.thehindu.com/youngworld
For further queries, call 1800 102 1878
For bulk bookings, email reach.youngworld@thehindu.co.in



CIN No: L15331KL1963PLC002028
Registered Office: Post Box No. 20, Solvent Road, Irinjalakuda, Kerala - 680 121
Ph: 0480 2825476 E-mail: ksekerala@gmail.com Web: www.kselimited.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

Rs. in lakhs

Particulars	Quarter ended			Half year ended		Year ended
	30.09.2025 Unaudited	30.06.2025 Unaudited	30.09.2024 Unaudited	30.09.2025 Unaudited	30.09.2024 Unaudited	31.03.2025 Audited
Total Income from Operations	43102.09	42053.34	41600.75	85155.43	84859.47	165759.45
Net Profit / (Loss) for the period (before tax, Exceptional and/or Extra-ordinary Items)	4374.50	5196.41	2057.27	9570.91	4536.53	12020.86
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extra-ordinary Items)	4374.50	5196.41	2305.32	9570.91	4784.58	12271.61
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extra ordinary items)	3287.18	3855.43	1713.22	7142.61	3550.03	9130.73
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	3307.55	3773.02	1612.39	7080.57	3390.13	9110.80
Paid up Equity Share Capital	320.00	320.00	320.00	320.00	320.00	320.00
Other Equity						29354.60
Earnings Per Equity Share of Rs.10 each (for continuing and discontinued operations) (not annualised)						
Basic (Rs.)	102.72	120.48	53.54	223.21	110.94	285.34
Diluted (Rs.)	102.72	120.48	53.54	223.21	110.94	285.34

Note: 1. The above is an extract of the detailed format of the Financial Results for the Quarter and Half year ended 30th September, 2025 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Half year ended 30th September, 2025 are available on the Stock Exchange website at www.bseindia.com and on the Company's website at www.kselimited.com.

2. The Annual General Meeting of Shareholders held on 20th September 2025 approved the sub-division of the Company's Equity shares in accordance with the provisions of Section 61(1)(d) and other applicable provisions of the Companies Act, 2013. Accordingly, each Equity share of face value ₹10 has been sub-divided into 10 Equity shares of face value ₹1 each. The record date for the share split was fixed as 28th October 2025, and consequently, from 29th October 2025, the face value per Equity share of KSE Limited stands at ₹1 fully paid-up. The total number of paid-up Equity shares of the Company now amounts to 3,20,00,000 shares. The Earnings Per Share (EPS) based on the original face value of ₹10, for the Quarter ended 30th September 2025 is ₹102.72 and for the Half-year ended 30th September 2025 is ₹223.21 After giving effect to the share split, the EPS for the Quarter and Half year stands adjusted to ₹10.272 and ₹22.321, respectively, based on the new face value of ₹1 per Equity share.



Irinjalakuda
6th November, 2025

For KSE Limited
Sd/-
M.P. JACKSON
(DIN 01889504)
Managing Director

